Publicaciones en las que colabora con Amaia Vilas Zornoza (17)

2023

  1. Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures

    Stem Cell Reports, Vol. 18, Núm. 1, pp. 64-80

  2. The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells

    EMBO Reports, Vol. 24, Núm. 5

2022

  1. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  2. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

  3. One-Step In Vitro Generation of ETV2-Null Pig Embryos

    Animals, Vol. 12, Núm. 14

2021

  1. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  2. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

  2. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

2019

  1. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

  2. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions

    Journal of Neuroinflammation, Vol. 16, Núm. 1

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

  2. Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells

    Oncotarget, Vol. 9, Núm. 16, pp. 12842-12852

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

  2. Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

    PLoS ONE, Vol. 12, Núm. 12

2009

  1. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

2008

  1. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840